AMGN

Latest SEC Filings & News for AMGN

7 most recent filings and news items mentioning AMGN. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/AMGN/news?limit=20"

Pull AMGN filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

Live On CNBC, Kevin Simpson Announces Bought More AbbVie; Bought More Amgen

Live On CNBC, Kevin Simpson Announces Bought More AbbVie; Bought More Amgen

View filing at SEC.gov →

Mizuho Maintains Neutral on Amgen, Raises Price Target to $303

Mizuho Maintains Neutral on Amgen, Raises Price Target to $303

View filing at SEC.gov →

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

View filing at SEC.gov →

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal

Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal

View filing at SEC.gov →

Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $340

Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $340

View filing at SEC.gov →

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

View filing at SEC.gov →

Amgen (Europe) GmbH issues employment offer to executive at CHF 1.07M annual salary

Amgen's European subsidiary extended an employment offer to Thomas Dittrich for an Executive Vice President position effective July 1, 2026, with an annual base salary of CHF 1.07 million. The hire represents standard executive recruitment and carries no material implications for

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.